Breast Cancer in 2024 and Beyond

Peter Beitsch, MD
Dallas Surgical Group, Dallas, TX, USA

Adam Brufsky, MD, PhD
Magee-Womens Cancer Program at the UPMC Hillman Cancer Center, Pittsburgh, PA, USA

Monica Fornier, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Peter Kaufman, MD
University of Vermont, Burlington, VT, USA

Reshma Mahtani, DO
University of Miami Health System, Miami, FL, USA

Kelly McCann, MD, PhD
UCLA Medicine, Los Angeles, CA, USA

Mark Pegram, MD
Stanford University School of Medicine, Stanford, CA, USA

William Sikov, MD
Women & Infants Hospital of Rhode Island, Providence, RI, USA

The meeting report will be based on the following topics

• Current and Emerging Biomarkers and Testing Methodologies in Breast Cancer
• Evolving Standards for Early-Stage HER2+ Breast Cancer
• Optimizing the Management of HER2+ mBC With Current and Emerging Agents
• HER2-Low Breast Cancer – Expanding the Spectrum of Targetability
• Current and Future Prospects for High-Risk, Early-Stage, Triple-Negative Breast Cancer
• Current and Investigational Approaches in Metastatic Triple-Negative Breast Cancer
• Expanding Options for High-Risk HR+, HER2– Early Breast Cancer
• Evolving Paradigms in HR+, HER2– Metastatic Breast Cancer
• New Targets in Breast Cancer
• General Discussion: Future Directions in Breast Cancer Treatment